An effective absorption behavior of insulin for diabetic treatment following intranasal delivery using porous spherical calcium carbonate in monkeys and healthy human volunteers

Diabetes Technology and Therapeutics

Volumn 5, Issue 1, 2003, Pages 1-9

  Haruta, Shunji ^a   Hanafusa, Takashi ^a   Fukase, Hiroyuki ^b   Miyajima, Hiroaki ^c   Oki, Toshikazu ^a  

^a Translational Research Ltd   (Japan)

^b CPC Clinic   (Japan)

^c SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; DRUG CARRIER; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MONKEY; MUCOSA INFLAMMATION; NONHUMAN; NORMAL HUMAN; NOSE MUCOSA; PARTICLE SIZE; POSTPRANDIAL STATE; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ADULT; ANIMALS; CALCIUM CARBONATE; DRUG CARRIERS; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; INTESTINAL ABSORPTION; KINETICS; MACACA FASCICULARIS; MALE; METABOLIC CLEARANCE RATE; MICROSCOPY, ELECTRON, SCANNING; REFERENCE VALUES; SOLUTIONS;

EID: 0037272797     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091503763816409     Document Type: Article

References (16)

1. Patton JS, Bukar J, Nagaraja S: Inhaled insulin. Adv Drug Deliv Rev 1999;35:235-247.
2. Hinchcliffe M, Illum L: Intranasal insulin delivery and therapy. Adv Drug Deliv Rev 1999;35:199-234.
3. Chien YW, Siddiqui O, Sun Y, Shi WM, Liu JC: Transdermal iontophoretic delivery of therapeutic peptides/proteins. I: Insulin. Ann NY Acad Sci 1987;507:32-51.
4. Damge C, Michel C, Aprahamian M, Couvreur P: New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 1998;37:246-251.
5. Modi P, Mihic M, Lewin A: The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist System. Diabetes Metab Res Rev 2002;18 Suppl 1):S38-S42.
6. Ritschel WA, Ritschel GB: Rectal administration of insulin. Methods Find Exp Cli Pharmacol 1984;6:513-529.
7. Skyler JS, Cefalu WT, Kourldes LA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001;357:331-335.
8. Farr SJ, McElduff A, Mather LE, Okikawa J, Ward ME, Gonda I, Licko V, Rubsamen RM: Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2000;2:185-197.
9. Brunner GA, Balent B, Ellmerer M, Schaupp L, Siebenhofer A, Jendle JH, Okikawa J, Pieber TR: Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001;44:305-308.
10. Jacobs MAJM, Schreuder RH, Jap-A-Joe K, Naruta JJ, Andersen PM, Heine RJ: The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers. Diabetes 1993;42:1649-1655.
11. Moses AC, Gordon GS, Carey MC, Flier JS: Insulin administered intranasally as an insulin-bile salt aerosol. Diabetes 1983;32:1040-1047.
12. Mishima M, Wakita Y, Nakano M: Studies on the promoting effects of medium chain fatty acid salts on the nasal absorption of insulin in rats. J Pharmacobiodyn 1987;10:624-631.
13. Yanagawa A: Nasally administerable compositions. European Patent Application 1996 (17 April);0 681 833 A3.
14. Ishikawa F, Katsura M, Tamai I, Tsuji A: Improved nasal bioavailability of elcatonin by insoluble powder formulation. Int J Pharm 2001;224:105-114.
15. Morimoto K, Katsumata H, Yabuta T, Iwanaga K, Kakemi M, Tabata Y, Ikada Y: Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Eur J Pharm Sci 2001;13:179-185.
16. Harris AS, Ohlin M, Svensson E, Lethagen S, Nilsson IM: Effect of viscosity on the pharmacokinetics and biological response to intranasal desmopressin. J Pharm Sci 1989;78:470-471.